



# UNITED STATES PATENT AND TRADEMARK OFFICE

*Handwritten signature/initials*

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/002,842	11/14/2001	James Hunter Boone	TLAB.79219	3654

5251 7590 06/02/2006

SHOOK, HARDY & BACON LLP  
INTELLECTUAL PROPERTY DEPARTMENT  
2555 GRAND BLVD  
KANSAS CITY,, MO 64108-2613

EXAMINER

COOK, LISA V

ART UNIT PAPER NUMBER

1641

DATE MAILED: 06/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

10/002,842

Applicant(s)

BOONE ET AL.

Examiner

Lisa V. Cook

Art Unit

1641

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 30 March 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-9, 12-16, 21 and 22 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-9, 12-16 and 21-22 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- |  |   |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892)  | 4) <input type="checkbox"/> Interview Summary (PTO-413)<br>Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)   | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152)             |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date <u>4/17/06</u> . | 6) <input type="checkbox"/> Other: _____  |

## **DETAILED ACTION**

### ***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 3/30/06 has been entered.

### ***Amendment Entry***

2. Applicant's amendment filed 3/7/06 is acknowledged. Claims 1 and 12 were modified. New claims 21 and 22 were added. Currently claims 1-9, 12-16, and 21-22 are pending and under consideration.

3. Objections and/or rejections of record not reiterated below have been withdrawn.

## **OBJECTIONS WITHDRAWN**

### ***Information Disclosure Statement***

4. The listing of references in the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609 A(1) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the examiner on form PTO-892 or applicant on PTO-1449 has cited the references they have not been considered.

Art Unit: 1641

5. The information disclosure statement filed 4/17/06 has been considered.

NEW GROUNDS OF REJECTION

*Claim Rejections - 35 USC § 103*

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

- I. Claims 1-5 and 21 are rejected under 35 U.S.C. 103(a) as being unpatentable over by Sugi et al. (The American Journal of Gastroenterology, Vol.91, No.5, 927-934, 1996) in view of Kruzel et al. (Advances in Experimental Medicine and Biology, 1998, 443, pages 167-173-Abstract Only).

Art Unit: 1641

Sugi et al. disclose that lactoferrin (LF) levels were elevated in fecal samples of patients with inflammatory bowel disease. The extracellular (endogenous) release of LF was the most efficient and stable inflammation maker found in feces. See abstract. LF was taught to be a superior maker for intestinal inflammation.

Specifically, LF was elevated in inflammatory bowel disease like active ulcerated colitis - UC and Crohn's disease - CD patients when compared to control subjects. See page 930, Table 1 and page 932, 1<sup>st</sup> column.

Mucosal measurements of LF in patients with inflammatory bowel disease (IBD) were also conducted to further characterize Lf as a marker (claim 4). See page 931 Discussion.

Lactoferrin concentrations were detected via an ELISA assay. The samples were diluted from 100- to 10,000 fold in 0.1M Tris-HCl buffer before testing (claims 2 and 3). A color (qualitative) reaction was measured at 510/630nm (claim 5). See page 928 2<sup>nd</sup> column 3<sup>rd</sup> paragraph. Sugi et al. teach elevation of lactoferrin in inflammatory diseases.

Sugi et al. differ from the instant invention in not specifically teaching that the non-elevation of lactoferrin indicates IBS in patients.

However, Kruzel et al. disclose the importance of lactoferrin in intestinal inflammation. Specifically lactoferrin is important in maintaining gastrointestinal balance. Lactoferrin is an iron binding protein found in high concentration in most human exocrine secretions. Lactoferrin is important in fighting toxic metabolites and antigenic components of potential pathogens (IBD). The specification teaches that IBS is an intestinal disorder of motility and the intestinal nervous system on page 2 lines 20-21. Accordingly, a non-elevation of lactoferrin would be indicative of non-IBD disorders such as IBS.

The diagnosis of non-inflammatory diseases when lactoferrin is not elevated is an obvious modification of the method determining wherein elevated lactoferrin is indicative of inflammatory disorders and the teaching of Kruzel showing that lactoferrin specifically is elevated to fight metabolites and pathogens (not intestinal disorders involving motility and the nervous system-IBS), thus the non elevation of lactoferrin would conclude the diagnoses of non-inflammatory etiologies (metabolites and/or pathogens) such as irritable bowel syndrome (IBS).

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to use the lactoferrin detection method employed by Sugi et al. and conclude that a patient had IBS when lactoferrin was not elevated as taught by Kruzel et al. because Kruzel et al. taught that lactoferrin is important in fighting toxic metabolites and antigenic components of potential pathogens (IBD). The specification teaches that IBS is an intestinal disorder of motility and the intestinal nervous system on page 2 lines 20-21. Accordingly, a non-elevation of lactoferrin would be indicative of non-IBD disorders such as IBS.

One of ordinary skill in the art would have been motivated to distinguish between IBD and IBS disorders in order to accurately identify the two disorders and treat patients with intestinal disorders appropriately.

II. Claims 6-9, 12, 14-16 and 22 are rejected under 35 U.S.C. 103(a) as being unpatentable over Sugi et al. (The American Journal of Gastroenterology, Vol.91, No.5, 927-934, 1996) in view of Kruzel et al. (Advances in Experimental Medicine and Biology, 1998, 443, pages 167-173- Abstract Only) and further in view of Peen et al. (Gut, 1993, 34, 56-62).

Please see Sugi et al. in view of Kruzel et al. as set forth above.

Art Unit: 1641

Sugi et al. in view of Kruzel et al. differ from the instant invention in not specifically teaching the utility of polyclonal antibodies at an optical density measurement of 450nm and greater than .200 in their assay procedures.

However, Pene et al. teach ELISA procedures measuring lactoferrin with these parameters. See page 57 –58. Pene et al. employed polyclonal rabbit anti-human lactoferrin from Sweden (claim 6). See page 58 Rabbit Anti-Lactoferrin Antisera. In the assay, plates were coated with the antigen and samples (antibody bound sample).

The bound complex was then exposed to alkaline-phosphatase conjugated rabbit human antibodies (enzyme linked antibody). The enzyme linked antibody bound sample complex was measured at 405nm at 1.0 (greater than 0.2). See page 57, 2<sup>nd</sup> column ELISA.

With respect to the optical density measurement being 450nm, this is deemed routine adjustment for optimizing the assays taught by Sugi et al. in view Kruzel et al. and further in view of Pene et al. Absent evidence to the contrary this detection parameter is routine optimization. This routine optimization position is supported by the instant disclosure on page 11 lines 14-20.

It would have been prima facie obvious to one of ordinary skill in the art at the time the invention was made to measure lactoferrin with polyclonal antibodies, at an optical density measurements at 450nm, greater than .200 as taught by Peen et al. in the method of Sugi et al. in view of Kruzel et al. because Peen et al. taught that their method was quick and accurate. See Figure 1 and page 59 2<sup>nd</sup> column.

Art Unit: 1641

***Response to Arguments***

7. Applicant's contends that the reference of Sugi et al. is silent with respect to the detection of non-elevated levels of lactoferrin. This argument was carefully considered and found persuasive. Accordingly the reference of Kruzel et al. has been added to make obvious the elevation of lactoferrin to fight against metabolites and pathogens in the intestine. This elevation is not related to motility and/or nervous system disorders of the intestine (IBS). Therefore the non-elevation of lactoferrin concludes that the intestinal disorder is IBS or related to motility and/or nervous system.

Applicant contends that the reference to Sugi et al. does not teach a diagnosis of irritable bowel syndrome and other non-inflammatory etiologies. However, a reference is not limited to its working examples but must be evaluated for what it teaches those of ordinary skill in the art. In re Boe, 355 F.2d 961, 148 USPQ 507 (CCPA 1966). In re Chapman, 357 F.2d 418, 148 USPQ 711 (CCPA 1966). In this case Sugi et al. in view of Kruzel disclose the elevation of lactoferrin in IBD disorders and teaches lactoferrin's key role in fighting metabolites and/or pathogens (not motility and nervous system intestinal disorders).

Applicant contends that the references do not teach or suggest the preclusion of non-inflammatory etiologies. Although the references teach the measurement of elevated lactoferrin in inflammatory diseases, they are silent with respect to non-inflammatory disorders. This argument was carefully considered but not found persuasive because Sugi et al. disclose the measurement of elevated lactoferrin as a marker for inflammatory disorders. Therefore the marker for inflammatory diseases would obviously preclude (rule out in advance) the detection of non-inflammatory events.

Art Unit: 1641

Applicant contends that the reference of Peen et. al. (1993) teaches the detection of lactoferrin in serum samples not in fecal samples. Applicant further contends that Peen et al. detects the presence of anti-lactoferrin human immunoglobulins, not endogenous lactoferrin. This argument was carefully considered but not found persuasive because the Peen et al. reference was not relied on for teaching fecal lactoferrin measurement. Sugi et al. are cited in combination with Peen et al. and Sugi et al. disclose fecal lactoferrin measurements.

With respect to Peen et al. only detecting anti-lactoferrin human immunoglobulins, it is noted that Peen et al. teach the detection of a complex formed between anti-lactoferrin human immunoglobulins and endogenous lactoferrin. See Peen et al. page 57 2<sup>nd</sup> column ELISA. Wherein human lactoferrin solutions were incubated in microtiter plates and subsequently detected. See Peen et al. page 58 1<sup>st</sup> column Western Blotting.

While a deficiency in a reference may overcome a rejection under 35 USC 103, a reference is not overcome by pointing out that a reference lacks a teaching for which other references are relied. In re Lyons, 364 F.2d 1005, 150 USPQ 741, 746 (CCPA 1966). Both Sugi et al. and Peen (1993) disclose elevated lactoferrin in inflammatory disorders and therefore they necessarily preclude the measurement on non-inflammatory disease.

8. For reasons aforementioned, no claims are allowed.

Art Unit: 1641

***Remarks***

9. Prior art made of record and not relied upon is considered pertinent to the applicant's disclosure:

A. Pool et al. (Gut, 1993, 34, 46-50) teach ELISA techniques to measure autoantibodies involved in inflammatory bowel disease.

B. Guerrant et al. (US Patent #5,124,252) teach in vitro fecal tests to measure lactoferrin.

10. Papers related to this application may be submitted to Group 1600 by facsimile transmission. Papers should be faxed to Group 1600 via the PTO Fax Center located in Crystal Mall 1. The faxing of such papers must conform to the notice published in the Official Gazette, 1096 OG 30 (November 15, 1989). The Group 1641 – Central Fax number is (571) 273-8300, which is able to receive transmissions 24 hours/day, 7 days/week. In the event Applicant would like to fax an unofficial communication, the Examiner should be contacted for the appropriate Right Fax number.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Lisa V. Cook whose telephone number is (571) 272-0816. The examiner can normally be reached on Monday - Friday from 7:00 AM - 4:00 PM.


If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le, can be reached on (571) 272-0823.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group TC 1600 whose telephone number is (571) 272-1600.

Art Unit: 1641

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR.

Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).



Lisa V. Cook  
Remsen 3C-59  
571-272-0816  
5/26/06



LONG V. LE  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

05/30/06